Characterizing clinical toxicity in cancer combination therapies.

Bioinformatics · 2026 · PMC12865850 · PMID 41537239

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In DrugBank, we found that the majority of synergy metrics show a highly significant overall difference among the toxicity groups ( p ≪ 0.05 ) ( Fig. 2C ).

also in 132,142 other papers

a clear trendno p-value reported

The Jonckheere-Terpstra tests verified a clear trend: higher target and pathway overlap consistently correlated with increased toxicity severity across both DrugBank and DDInter databases.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.